AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (fast washout)
Number of subjects: 46
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (slow washout)
Number of subjects: 46
Study 1739574 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (fast washout)
Number of subjects: 46
Study 6691715 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA (oral methoxsalen plus longwave UV light)
Number of subjects: 183
Study 6691715 — intervention group
Group type: COMPARATOR
Intervention: UV-B therapy
Number of subjects: 183
Study 6691715 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 183
Study 6691715 — intervention group
Group type: EXPERIMENTAL
Intervention: UV-B phototherapy
Number of subjects: 183
Study 6691715 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra UV-B treatment to leg lesions
Number of subjects: 183
Study 29649827 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe driving skill program consisting of 10 1-hour classroom sessions and 10 1-hour on-road sessions
Number of subjects: 160
Study 29649827 — intervention group
Group type: COMPARATOR
Intervention: 1 classroom education (Control)
Number of subjects: 160
Study 29498550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI; 412 hr, $4,373 per participant)
Number of subjects: 325
Study 29498550 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI)
Number of subjects: 325
Study 27141894 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive T2DM prediction model (model 4)
Number of subjects: 12285
Study 27141894 — intervention group
Group type: COMPARATOR
Intervention: FINDRISC model
Number of subjects: 12285
Study 24705203 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Number of subjects: 0
Study 22364419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 481
Study 22364419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 300 mg daily
Number of subjects: 481
Study 22364419 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 200 mg daily
Number of subjects: 481
Study 20738472 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment (specific treatment not detailed)
Number of subjects: 0
Study 20738472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19127033 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Abciximab
Number of subjects: 0
Study 19127033 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa inhibitors (GPI), specifically Tirofiban
Number of subjects: 0
Study 15369998 — intervention group
Group type: EXPERIMENTAL
Intervention: Maori participants
Number of subjects: 205
Study 15369998 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Maori participants
Number of subjects: 205
Study 15369998 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants (Maori and non-Maori)
Number of subjects: 205
Study 15369998 — intervention group
Group type: COMPARATOR
Intervention: Categorical ethnicity distinction (Maori and non-Maori)
Number of subjects: 205
Study 11600526 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydroepiandrosterone (50 mg/d)
Number of subjects: 22
Study 11600526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9539984 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (IT) for IDDM
Number of subjects: 99
Study 9539984 — intervention group
Group type: COMPARATOR
Intervention: Control group (refusers)
Number of subjects: 99
Study 8026248 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (30-60 mg/day for 12.6 ± 2.6 months)
Number of subjects: 11
Study 2910633 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 15
Study 2910633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 141904 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine postoperative physiotherapy
Number of subjects: 16
Study 141904 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive physiotherapy
Number of subjects: 16
Study 141904 — intervention group
Group type: COMPARATOR
Intervention: Meniscectomy patients
Number of subjects: 16
Study 141904 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteer controls
Number of subjects: 16
Study 31944371 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy for Adolescents (DBT-A)
Number of subjects: 35
Study 31944371 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual plus group sessions (TAU + GS)
Number of subjects: 35
Study 30346097 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased temperature (average of 1.4°C over a growing season) and additional rainwater (10% of the monthly mean added weekly, 40% total)
Number of subjects: 24
Study 30346097 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 24
Study 27727268 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aerosol containing chlorfenvinphos 4.8%, dichlorphos 0.75% and gentian violet 0.145%
Number of subjects: 55
Study 27727268 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 55
Study 25153952 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive mood induced by showing comedy movie clips to 100 participants
Number of subjects: 200
Study 25153952 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood induced by showing tragedy movie clips to another 100 participants
Number of subjects: 200
Study 25153952 — intervention group
Group type: COMPARATOR
Intervention: Both mood states were assessed in decision making under uncertainty
Number of subjects: 200
Study 22577354 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of glucosamine sulfate and NSAIDs
Number of subjects: 0
Study 22577354 — intervention group
Group type: COMPARATOR
Intervention: Glucosamine sulfate
Number of subjects: 0
Study 21116009 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-continuous live HVPC for 72 h postinjury
Number of subjects: 50
Study 21116009 — intervention group
Group type: COMPARATOR
Intervention: Placebo HVPC for 72 h postinjury
Number of subjects: 50
Study 18937609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 30
Study 18937609 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronised fenofibrate 200 mg/day
Number of subjects: 30
Study 18937609 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day plus micronised fenofibrate 200 mg/day
Number of subjects: 30
Study 15953425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone (4 mg)
Number of subjects: 60
Study 15953425 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar injections of triamcinolone (40 mg, three times)
Number of subjects: 60
Study 14654745 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐CBP
Number of subjects: 30
Study 14654745 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐CBP
Number of subjects: 30
Study 14654745 — intervention group
Group type: COMPARATOR
Intervention: S‐HBP
Number of subjects: 30
Study 10942856 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg sublingual buprenorphine (BUP)
Number of subjects: 3
Study 10942856 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg sublingual buprenorphine (BUP)
Number of subjects: 3
Study 10942856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 10942856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg buprenorphine (detoxification)
Number of subjects: 3
Study 10942856 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 3
Study 8774028 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (exact dosage not specified)
Number of subjects: 93
Study 8774028 — intervention group
Group type: COMPARATOR
Intervention: Control (normal practice)
Number of subjects: 93
Study 1352868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid derivative (bis-hemisuccinate bisodic salt) at a dose of 600 mg/day for 6 months
Number of subjects: 40
Study 1352868 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 40
Study 6376317 — intervention group
Group type: EXPERIMENTAL
Intervention: Large mediastinal masses (MT ratio >= 0.35)
Number of subjects: 154
Study 6376317 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate mediastinal invasion (MT ratio < 0.35)
Number of subjects: 154
Study 6376317 — intervention group
Group type: EXPERIMENTAL
Intervention: No mediastinal involvement
Number of subjects: 154
Study 6376317 — intervention group
Group type: COMPARATOR
Intervention: Combined modality therapy utilizing MOPP chemotherapy
Number of subjects: 154
Study 31080129 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body MRI (WB-MRI)
Number of subjects: 353
Study 31080129 — intervention group
Group type: COMPARATOR
Intervention: Standard pathways
Number of subjects: 353
Study 30026333 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.05 mg
Number of subjects: 705
Study 30026333 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 0.3 mg
Number of subjects: 705
Study 30026333 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.3 mg
Number of subjects: 705
Study 30026333 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 705
Study 30026333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 705
Study 26824731 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) supplements
Number of subjects: 18775
Study 26824731 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MMN) supplements
Number of subjects: 18775
Study 26824731 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA) supplements
Number of subjects: 18775
Study 25946854 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% solution of ascorbic acid, 20 ml/day for 20 days
Number of subjects: 185
Study 25946854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin, 20 ml (10.0 ml/drip 2 times a day) for 10 days
Number of subjects: 185
Study 25946854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin, extended to 20 days with a dose of 10 ml/day from 11th to 20th day
Number of subjects: 185
Study 25946854 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoflavin for 20 days in patients with 18-20 points on NIH scale
Number of subjects: 185
Study 22500384 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine + Fuzheng Huayu Capsule (FHC)
Number of subjects: 80
Study 22500384 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine alone (Control)
Number of subjects: 80
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 40 mg
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 7492
Study 20569451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene or Raloxifene
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (Bazedoxifene and Raloxifene)
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg and 40 mg
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7492
Study 20569451 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 7492
Study 17943542 — intervention group
Group type: EXPERIMENTAL
Intervention: dydrogesterone 20 mg/day
Number of subjects: 1173
Study 17943542 — intervention group
Group type: EXPERIMENTAL
Intervention: dydrogesterone 30 mg/day
Number of subjects: 1173
Study 15925752 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug therapy
Number of subjects: 6083
Study 12036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg/day)
Number of subjects: 17
Study 12036194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12036194 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 17
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of morphine (PCA)
Number of subjects: 161
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tramadol (PCA)
Number of subjects: 161
Study 10101626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PCA)
Number of subjects: 161
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (escape medication for non-responders)
Number of subjects: 161
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose
Number of subjects: 161
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading dose and pain scores during the first 30 min
Number of subjects: 161
Study 10101626 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to post-operative pain management
Number of subjects: 161
Study 7593695 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 different types of manual toothbrush
Number of subjects: 30
Study 7593695 — intervention group
Group type: EXPERIMENTAL
Intervention: Planimetric plaque area method
Number of subjects: 30
Study 7593695 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical or nonclinical personnel analysis
Number of subjects: 30
Study 3314516 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% dextrose (50 gm of glucose)
Number of subjects: 32
Study 3314516 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 32
Study 3314516 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 32
Study 28893574 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation over left DLPFC
Number of subjects: 20
Study 28893574 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over left DLPFC
Number of subjects: 20
Study 26386702 — intervention group
Group type: EXPERIMENTAL
Intervention: HES outpatient dataset
Number of subjects: 370
Study 25632745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongfu Jinghua Decoction (TJD) combined with conventional Western medical treatment
Number of subjects: 60
Study 25632745 — intervention group
Group type: COMPARATOR
Intervention: Conventional Western medical treatment alone
Number of subjects: 60
Study 23349296 — intervention group
Group type: EXPERIMENTAL
Intervention: Na/K citrate
Number of subjects: 202
Study 23349296 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 202
Study 18523036 — intervention group
Group type: EXPERIMENTAL
Intervention: Difflam throat spray
Number of subjects: 45
Study 18523036 — intervention group
Group type: COMPARATOR
Intervention: Placebo throat spray
Number of subjects: 45
Study 18640466 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b 250 microg
Number of subjects: 71
Study 18640466 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1b 500 microg
Number of subjects: 71
Study 18640466 — intervention group
Group type: COMPARATOR
Intervention: MRI evaluation
Number of subjects: 71
Study 20961349 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-pulse Nd:YAG laser
Number of subjects: 20
Study 20961349 — intervention group
Group type: COMPARATOR
Intervention: Combination Q-switched Nd:YAG laser with topical carbon lotion followed by long-pulse Nd:YAG
Number of subjects: 20
Study 15705723 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting a specific sound pressure level
Number of subjects: 30
Study 15705723 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking twice as loud as comfortable
Number of subjects: 30
Study 15705723 — intervention group
Group type: EXPERIMENTAL
Intervention: Speaking in noise
Number of subjects: 30
Study 11558980 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Education Programme (PEP)
Number of subjects: 313
Study 11558980 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 313
Study 9141936 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive ketamine (0.5 mg/kg followed by infusion of 10 micrograms.kg‐1.min‐1 until abdominal closure)
Number of subjects: 40
Study 9141936 — intervention group
Group type: COMPARATOR
Intervention: Postwound closure ketamine (0.5 mg/kg immediately after abdominal closure)
Number of subjects: 40
Study 8494755 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education package (pamphlets, workbooks, video)
Number of subjects: 543
Study 8494755 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing sunscreen
Number of subjects: 543
Study 8494755 — intervention group
Group type: EXPERIMENTAL
Intervention: Covering up in the sun
Number of subjects: 543
Study 8494755 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting in the shade
Number of subjects: 543
Study 3556308 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (0.5 mg PGE2 in 2.5 ml Triacetin gel, Prepidil, intracervically)
Number of subjects: 100
Study 3556308 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin induction without pretreatment (control)
Number of subjects: 100
Study 3556308 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel administration
Number of subjects: 100
Study 3556308 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 100
Study 3556308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical priming with PGE2
Number of subjects: 100
Study 3556308 — intervention group
Group type: COMPARATOR
Intervention: No cervical priming (control)
Number of subjects: 100
Study 3556308 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 gel group
Number of subjects: 100
Study 3556308 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin group (control)
Number of subjects: 100
Study 3556308 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE2 treatment
Number of subjects: 100
Study 11478762 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient appetite normaliser formulation (neogadine) administered for up to 30 days
Number of subjects: 722
Study 30884155 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage intervention conducted by mothers for 2 weeks
Number of subjects: 112
Study 30884155 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 112
Study 29861804 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 60
Study 29861804 — intervention group
Group type: COMPARATOR
Intervention: Trigger Points (TrP) release by ischemic compression method
Number of subjects: 60
Study 26962106 — intervention group
Group type: EXPERIMENTAL
Intervention: 6R-BH4 (sapropterin dihydrochloride)
Number of subjects: 32
Study 26962106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 23552390 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness-Based Therapy (MBT), 6 sessions over 3 weeks
Number of subjects: 0
Study 23552390 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study 22490903 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg daily for 30 days
Number of subjects: 108
Study 22490903 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg daily for 30 days
Number of subjects: 108
Study 22490903 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 150 mg group
Number of subjects: 108
Study 20354090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 percent cetylpyridinium chloride (CPC)
Number of subjects: 60
Study 20354090 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 percent chlorhexidine (CHX)
Number of subjects: 60
Study 20354090 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 60
Study 20354090 — intervention group
Group type: COMPARATOR
Intervention: No rinsing
Number of subjects: 60
Study 17241506 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (n = 15)
Number of subjects: 45
Study 17241506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (n = 15)
Number of subjects: 45
Study 17241506 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 45
Study 15744240 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccine before stem cell collection
Number of subjects: 61
Study 15744240 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 vaccine after autoHCT
Number of subjects: 61
Study 15744240 — intervention group
Group type: COMPARATOR
Intervention: No vaccine before stem cell collection
Number of subjects: 61
Study 11929445 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention about tardive dyskinesia
Number of subjects: 56
Study 11929445 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 56
Study 11929445 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 56
Study 9484992 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 0
Study 9484992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9484992 — intervention group
Group type: EXPERIMENTAL
Intervention: -455AA genotype
Number of subjects: 0
Study 7709282 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar belt
Number of subjects: 22
Study 7709282 — intervention group
Group type: COMPARATOR
Intervention: No lumbar belt
Number of subjects: 22
Study 2663735 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime 200 mg twice daily (plus placebo once daily)
Number of subjects: 60
Study 2663735 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 500 mg/125 mg thrice daily
Number of subjects: 60
Study 1106196 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic cephalosporins
Number of subjects: 48
Study 1106196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 31615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preserved brimonidine 0.15%
Number of subjects: 21
Study 31615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free brimonidine 0.15%
Number of subjects: 21